PROTAC induces HIV-1 Nef degradation

Crunkhorn, Sarah

doi:10.1038/d41573-024-00060-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Disease X1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While PROTAC technology has been primarily exploited within the anticancer field [195][196][197], its application in the antiviral area is gaining attention [198][199][200][201]. Specifically, PROTAC compounds may be potentially developed against a broad range of viruses by customizing the recruiting ligands to different viral polymerases.…”

Section: Disease Xmentioning

confidence: 99%

Small Molecule Drugs Targeting Viral Polymerases

Palazzotti,

Sguilla,

Manfroni

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Small molecules that specifically target viral polymerases—crucial enzymes governing viral genome transcription and replication—play a pivotal role in combating viral infections. Presently, approved polymerase inhibitors cover nine human viruses, spanning both DNA and RNA viruses. This review provides a comprehensive analysis of these licensed drugs, encompassing nucleoside/nucleotide inhibitors (NIs), non-nucleoside inhibitors (NNIs), and mutagenic agents. For each compound, we describe the specific targeted virus and related polymerase enzyme, the mechanism of action, and the relevant bioactivity data. This wealth of information serves as a valuable resource for researchers actively engaged in antiviral drug discovery efforts, offering a complete overview of established strategies as well as insights for shaping the development of next-generation antiviral therapeutics.

show abstract